A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00254436

Enrollment

Registered

2005-11-16

Start date

2001-10-31

Completion date

2004-06-29

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer, Rectal Cancer

Keywords

Epoetin Alfa, Epogen, Erythropoietin

Brief summary

To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed by surgery.

Detailed description

Anemia and fatigue are common problems in gastric and rectal cancer subjects at the completion of chemoradiation therapy and surgery. Results of several studies in cancer subjects suggest that treatment with epoetin alfa may be effective in maintaining hemoglobin levels, thereby reducing fatigue, decreasing transfusion requirement, and potentially improving quality of life.

Interventions

DRUGProcrit (epoetin alfa)

Weekly dose

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male or female 18 years of age or older * Must have a confirmed diagnosis of gastric or rectal cancer for whom the treatment plan is preoperative chemoradiation followed by surgery * Must have a baseline hemoglobin \>/= 10 g/dl and \< 15 g/dl * Must have adequate hematologic function * Must have life expectancy of more than 6 months * Karnofsky performance status of at least 50% * Must have adequate renal function * Patients with reproductive potential must use an adequate contraceptive method during treatment and three months after completing treatment * Patients must be able to read, understand, and complete the three Quality of Life questionnaires in English.

Exclusion criteria

* Prior chemotherapy for patients with rectal cancer * Gastric cancer patients who have received more than 2 cycles of chemotherapy * Anemia due to factors other than cancer/chemotherapy * Patients with prior treatment with epoetin alfa or any investigational forms of erythropoietin within the previous 6 months * Known hypersensitivity to mammalian-cell derived products or to human albumin * Pregnant or lactating women * Untreated Central Nervous System metastases * Any significant, uncontrolled disease/dysfunction of any of the major organs * Uncontrolled hypertension or history of uncontrolled cardiac arrhythmias, pulmonary embolism, thrombosis * New onset or poorly controlled seizures * History of active second malignancy * Major infection requiring hospitalization and antibiotics or surgery within 14 days of study entry * Blood transfusion within 1 month of study entry * Androgen therapy within 2 months of study entry

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients with Reduction in Red Blood Cell Transfusions	2 years	—
Patient Iron Levels	Every 4 weeks	Iron stores drawn at baseline and every four weeks.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026